A total of 60 clinical isolates of Paracoccidioides brasiliensis were tested for susceptibility to sulfadiazine and sulfadimethoxyne by the agar dilution technique. A modification of the Mueller-Hinton medium was devised which gave good growth of the yeast form. The minimum inhibitory concentrations for only 51.6% of the isolates were in the range of the recommended blood serum concentration (50 ,ug/ml (7, 14) .
A total of 60 clinical isolates of Paracoccidioides brasiliensis were tested for susceptibility to sulfadiazine and sulfadimethoxyne by the agar dilution technique. A modification of the Mueller-Hinton medium was devised which gave good growth of the yeast form. The minimum inhibitory concentrations for only 51.6% of the isolates were in the range of the recommended blood serum concentration (50 ,ug/ml). For 6 to 8% of the isolates, the miimum inhibitory concentrations were above 200 ,ug of both sulfadiazine and sulfadimethoxyne per ml. A significant decrease in susceptibility was demonstrated for one isolate obtained from a patient relapsing during sulfonamide therapy.
Sulfonamides, both rapid and slow-acting compounds, have been the antimicrobial agents most frequently employed in the treatment of paracoccidioidomycosis. Results of extensive trials have indicated that adequate responses are obtained in approximately 70 .0% of the patients subjected to continuous and prolonged therapy (3, (10) (11) (12) . Clinical observations have also revealed that relapses occur in approximately 10% of the cases, presumably because of fungal resistance acquired during the course of inadequate treatment. Some patients, however, appear refractory to sulfonamides from the beginning of sulfonamide therapy, suggesting infection with a sulfonamide-resistant strain (7, 14) .
In spite of these observations, there has been no survey of the in vitro susceptibility of the causative agent, Paracoccidioides brasiliensis, to sulfonamides. Earlier studies either employed complex culture media, which could have antagonized the effect of the drug, or made use of the fungus mycelial phase, which is different from the phase found in tissues, that is, the yeast phase of this dimorphic fungus (5, 8, 15) . Consequently, the results of such studies have not clarified whether resistance can be present de novo or be acquired. One ofthe difficulties which may have deterred such studies is the difficulty of obtaining adequate growth of the yeast phase in media appropriate for susceptibility testing within a period of time compatible with drug activity (21, 22) .
This report describes the procedure developed for sulfonamide susceptibility testing and presents data on the susceptibility pattern of 60 different isolates of P. brasiliensis to sulfadiazine and sulfadimethoxyne.
MATERIALS AND METHODS
Fungi. Sixty-five isolates of P. brasiliensis were used in this study. All were from clinical sources (Colombian patients) and represented the original isolate at time of diagnosis, with the exception of three which were obtained during relapses. The stock cultures were kept in Sabouraud glucose agar at approximately 25°C. When needed, they were converted to the yeast phase by subculturing in the special media described below and incubated at 36°C. Identity confirmation was obtained by demonstration of dimorphism and by the characteristic microscopical appearance, multiple budding yeast cells, in cultures incubated at 360C.
Culture media. It was necessary to find a medium which would not antagonize sulfonamides and which, at the same time, could promote abundant growth of P. brasiliensis. Earlier attempts to culture the fungus in the conventional Mueller-Hinton medium (BBL Microbiology Systems, Cockeysville, Md.) used for sulfonamide susceptibility testing of bacteria, proved unsuccessful (4, 22) . A series of experiments was performed by enriching such a medium with various chemicals known to promote growth in the fungus (1, 17 This medium plus the sulfonamides (see below) was gently but thoroughly mixed, poured into sterile standard 60-mm petri dishes, and allowed to harden at room temperature. It was then checked for sterility by overnight incubation at 36°C. The medium was utilized within 24 h of preparation. Antimicrobial agents. Reference preparations of sulfadiazine and sulfadimethoxyne as representatives of rapid and slow acting sulfonamides, respectively, were purchased from U.S. Pharmacopeia Conventions, Inc. (Rockville, Md.). They were used as specified by the manufacturer, including heating of sulfadimethoxyne at 105°C for 3 h. Specified amounts of both drugs were solubilized in 2.0-ml quantities of sterile warm water plus a minimal amount of 10% NaOH (22), added dropwise.
Agar dilution method. Dilutions of antifungal agents in sterile distilled water were prepared at 10 times the concentrations required in the final test.
Serial twofold dilutions ranging from 125 to 2,000 jig of each drug per ml were used. The appropriate amount of MMH was prepared in screw-capped bottles, autoclaved, and kept in the water bath as previously indicated. After addition of the thiamine, 1 volume of the corresponding antimicrobial agent was added to each 9 volumes of MMH agar. This was swirled and poured into the plates. Control plates without sulfonamides were also prepared (19, 22 Five of the strains showing no diminished growth at 200 ,ug/ml were serially tested in the presence of 300, 400, and 600 jig/ml. The results indicate that 300 ,tg/ml represented the minimum inhibitory concentrations for all the isolates. 
DISCUSSION
The results of this study indicate that it is possible to determine the susceptibility of P. brasiliensis to sulfonamides on a regular basis. The simplicity and availability of the required culture medium (MMH) would make in vitro testing feasible for most myocology centers, especially for those located in the endemic paracoccidioidomycosis area.
In vitro testing of sulfonamides by the agar dilution procedure has proved satisfactory for bacteria, but endpoints must be taken on the basis of sudden, sharp (80%) diminution of growth. The carryover of sulfonamide antagonists in the inoculum may allow some growth even in the highest drug concentration (22) . Our data cannot be compared with that in earlier reports (5, 8, 15) , either because former testing was done with the mycelial phase or because complex culture media were used. The choice of medium is critical, since many are unsuitable because of their content ofp-aminobenzoic acid or other sulfonamide antagonists (2, 9, 22) . The modified Mueller-Hinton medium used in our experiments adds no antagonists to the classic formulation and has the advantage ofsupporting good growth of over 90% of the P. brasiliensis isolates.
Shortly after introduction of sulfonamide therapy, it was suggested that sulfonamide blood concentrations of 50 ,ig/ml were sufficient to control paracoccidioidomycosis (13) . The classical therapeutic scheme, 3,000 to 6,000 mg of sulfadiazine or 500 mg of sulfamethoxypyridazine per day, produces such concentrations (10, 11) . We studied antifungal concentrations encompassing the blood levels attainable in patients (20) . It was surprising to observe that the "effective" recommended concentration (50 ,tg/ 6 to 8% of isolates grew abundantly in the presence of such high sulfonamide levels. Mackinnon, using adequate culture medium but prolonged 300C incubation, recorded only partial inhibition of his 6 isolates with 150 ,ug of sulfadiazine per ml (8) . It is tempting to postulate a correlation between the in vitro findings and the recorded proportion of patients refractory to sulfonamide treatment from the start of therapy (7, 8, 14, 16, 18) .
Because the majority of the isolates tested were obtained before therapy, it becomes apparent that P. brasiliensis is not homogeneously susceptible to sulfonamides and that de novo resistance can be found in a small, albeit important, number of isolates. By "resistance" we imply strains not susceptible to attainable drug levels, 100 to 150 ,ig/ml (20) .
As illustrated by the difference in susceptibility of the original and the relapse isolates obtained from one patient, resistance can be acquired. This may explain therapy failures in patients who had initially responded but became refractory shortly afterwards or when control of a relapse in a previously treated patient proved unsuccessful (7, 14) .
There was no difference in the susceptibility of the isolates to either one of the compounds used in this study; this finding corroborates clinical observations. It has been shown that there is no difference in therapeutic activity of various sulfonamides and that a refractory case does not improve by the change of agent (7) .
In paracoccidioidomycosis, successful therapeutic outcome has. been shown to depend on the continued prolonged use (3 to 5 years) of sulfonamides. These agents are fungistatic and require cooperation of the patient's immune defenses to achieve a cure (10, 11) . Consequently, the results of in vitro testing furnish only ancillary evidence, which explains both lack of response to appropriate sulfonamide dosing and relapses after faulty treatment schedules. However, our findings provide evidence of variation of susceptibility among isolates and acquisition of resistance after inadequate therapy. Such evidence should be taken into consideration when sulfonamide therapy is being considered for a patient, be it a new case or one relapsing after previous treatment.
